Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer

Donovan, Jenny L., Hamdy, Freddie C., Lane, J. Athene, Mason, Malcolm ORCID: https://orcid.org/0000-0003-1505-2869, Metcalfe, Chris, Walsh, Eleanor, Blazeby, Jane M., Peters, Tim J., Holding, Peter, Bonnington, Susan, Lennon, Teresa, Bradshaw, Lynne, Cooper, Deborah, Herbert, Phillipa, Howson, Joanne, Jones, Amanda, Lyons, Norma, Salter, Elizabeth, Thompson, Pauline, Tidball, Sarah, Blaikie, Jan, Gray, Catherine, Bollina, Prasad, Catto, James, Doble, Andrew, Doherty, Alan, Gillatt, David, Kockelbergh, Roger, Kynaston, Howard ORCID: https://orcid.org/0000-0003-1902-9930, Paul, Alan, Powell, Philip, Prescott, Stephen, Rosario, Derek J., Rowe, Edward, Davis, Michael, Turner, Emma L., Martin, Richard M. and Neal, David E. 2016. Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. New England Journal of Medicine 375 , pp. 1425-1437. 10.1056/NEJMoa1606221

Preview

PDF - Published Version Download (524kB) | Preview

Abstract

BACKGROUND Robust data on patient-reported outcome measures comparing treatments for clinically localized prostate cancer are lacking. We investigated the effects of active monitoring, radical prostatectomy, and radical radiotherapy with hormones on patient-reported outcomes. METHODS We compared patient-reported outcomes among 1643 men in the Prostate Testing for Cancer and Treatment (ProtecT) trial who completed questionnaires before diagnosis, at 6 and 12 months after randomization, and annually thereafter. Patients completed validated measures that assessed urinary, bowel, and sexual function and specific effects on quality of life, anxiety and depression, and general health. Cancer-related quality of life was assessed at 5 years. Complete 6-year data were analyzed according to the intention-to-treat principle. RESULTS The rate of questionnaire completion during follow-up was higher than 85% for most measures. Of the three treatments, prostatectomy had the greatest negative effect on sexual function and urinary continence, and although there was some recovery, these outcomes remained worse in the prostatectomy group than in the other groups throughout the trial. The negative effect of radiotherapy on sexual function was greatest at 6 months, but sexual function then recovered somewhat and was stable thereafter; radiotherapy had little effect on urinary continence. Sexual and urinary function declined gradually in the active-monitoring group. Bowel function was worse in the radiotherapy group at 6 months than in the other groups but then recovered somewhat, except for the increasing frequency of bloody stools; bowel function was unchanged in the other groups. Urinary voiding and nocturia were worse in the radiotherapy group at 6 months but then mostly recovered and were similar to the other groups after 12 months. Effects on quality of life mirrored the reported changes in function. No significant differences were observed among the groups in measures of anxiety, depression, or general health-related or cancer-related quality of life. CONCLUSIONS In this analysis of patient-reported outcomes after treatment for localized prostate cancer, patterns of severity, recovery, and decline in urinary, bowel, and sexual function and associated quality of life differed among the three groups.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Publisher:	Massachusetts Medical Society
ISSN:	0028-4793
Date of First Compliant Deposit:	14 December 2017
Last Modified:	05 May 2023 07:17
URI:	https://orca.cardiff.ac.uk/id/eprint/103419

Citation Data

Cited 951 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item